Has Ralph Oiknine, MD received payments from drug or device companies?

Yes. Drug and device makers reported $414,159 in general payments to Ralph Oiknine, MD across 595 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ralph Oiknine, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ralph Oiknine, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ralph Oiknine, MD

Endocrinology, Diabetes & Metabolism · Chesterfield, MONPI 1255365581

Payments from drug & device makers

$414,159in general payments, 2019–2025

Across 595 payments — averaging $696.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Senseonics, Incorporated$264K
Novo Nordisk$33K
AstraZeneca$29K
AbbVie$21K
Johnson & Johnson$18K
Boehringer Ingelheim$15K
plus $33K from 44 others

$1,685in research payments, 2019–2025

Across 1 payment — averaging $1685.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$2K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Senseonics, Incorporated	49	$263,720
Novo Nordisk	70	$33,248
AstraZeneca(2 entities)	69	$29,461
AbbVie	39	$21,476
Johnson & Johnson	34	$18,192
Boehringer Ingelheim	49	$14,808
Lilly USA, LLC	30	$8,289
Eli Lilly	4	$7,485
Insulet Corporation	6	$5,027
Sanofi-aventis U.S. LLC	16	$2,830
Valeritas, Inc.	7	$2,296
Medtronic(2 entities)	26	$2,024
Abbott	30	$1,605
Ascensia Diabetes Care US Inc.	9	$771
Sequel Med Tech, LLC	14	$319
Dexcom, Inc.	20	$271
BETA Bionics, Inc.	11	$256
Mannkind Corporation	10	$209
Amgen(2 entities)	10	$168
Novartis	10	$159
Bayer	9	$152
Xeris Pharmaceuticals, Inc.	8	$140
Corcept Therapeutics	5	$126
Tandem Diabetes Care, Inc.	1	$115
Merck	6	$101
Radius Health, Inc.	4	$96
Amarin Pharma, Inc.	6	$81
Lifescan, Inc.	4	$67
Intuity Medical Inc	4	$63
Antares Pharma, Inc.	4	$62
IBSA Pharma Inc.	3	$56
Kyowa Kirin, Inc.	2	$53
Nevro Corp.	3	$46
Ascendis Pharma Endocrinology Inc	2	$43
Pfizer	2	$35
Recordati_rare_diseases_inc.	2	$34
Amphastar Pharmaceuticals, Inc.	2	$33
Lexicon Pharmaceuticals, Inc.	2	$33
Endo Pharmaceuticals Inc.	2	$29
Zealand Pharma US, Inc.	1	$23
Sun Pharmaceutical Industries Inc.	1	$19
Halozyme Inc	1	$18
Ipsen Biopharmaceuticals, Inc	1	$17
Regeneron Healthcare Solutions, Inc.	1	$17
VBI Vaccine (delaware) Inc.	1	$16
RGH Enterprises LLC	1	$16
EUSA Pharma (US) LLC	1	$15
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$14
Kowa Pharmaceuticals America, Inc.	1	$13
Takeda Pharmaceuticals U.S.A., Inc.	1	$11

How this compares

$414,159 in reported general payments places this provider in the 95th percentile of 182 endocrinology, diabetes & metabolism providers in Missouri.

See all endocrinology, diabetes & metabolism providers in Missouri →

Medicare billing

Part B allowed, 2024

$706,715

Medicare patients

879

Services billed

12,913

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Chesterfield

Karen Chang-ChenChesterfield$640K
Norman FishmanChesterfield$352K
Soumya NadellaChesterfield$8K
Ralph DudaSpringfield$3M
Thomas NickolasSaint Louis$945K
Anne GoldbergSaint Louis$830K
Janet McGillSaint Louis$828K
Christopher CaseJefferson City$692K
Gregory LedgerSpringfield$690K
Alan RaubaJefferson City$594K

See the full list for Missouri →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →